Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Purpose: To update the American Society of Clinical Oncology (ASCO) guideline for antiemetics in oncology. Methods: A systematic review of the medical literature was completed to inform this update. MEDLINE, the Cochrane Collaboration Library, and meeting materials from ASCO and the Multinational Association for Supportive Care in Cancer were all searched. Primary outcomes of interest were complete response and rates of any vomiting or nausea. Results: Thirty-seven trials met prespecified inclusion and exclusion criteria for this systematic review. Two systematic reviews from the Cochrane Collaboration were identified; one surveyed the pediatric literature. The other compared the relative efficacy of the 5-hydroxytryptamine-3 (5-HT 3 ) receptor antagonists. Recommendations: Combined anthracycline and cyclophosphamide regimens were reclassified as highly emetic. Patients who receive this combination or any highly emetic agents should receive a 5-HT 3 receptor antagonist, dexamethasone, and a neurokinin 1 (NK 1 ) receptor antagonist. A large trial validated the equivalency of fosaprepitant, a single-day intravenous formulation, with aprepitant; either therapy is appropriate. Preferential use of palonosetron is recommended for moderate emetic risk regimens, combined with dexamethasone. For low-risk agents, patients can be offered dexamethasone before the first dose of chemotherapy. Patients undergoing high emetic risk radiation therapy should receive a 5-HT 3 receptor antagonist before each fraction and for 24 hours after treatment and may receive a 5-day course of dexamethasone during fractions 1 to 5. The Update Committee noted the importance of continued symptom monitoring throughout therapy. Clinicians underestimate the incidence of nausea, which is not as well controlled as emesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting
Ezzo, J., Richardson, M. A., Vickers, A., Allen, C., Dibble, S., Issell, B. F., Lao, L., Pearl, M., Ramirez, G., Roscoe, J. A., et al. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002285.pub2 · Cited by 341
RetractedSerotonin receptor antagonists for highly emetogenic chemotherapy in adults
Billio, A., Morello, E., & Clarke, M. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006272.pub2 · Cited by 68
RetractedSEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,783
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-79 · Cited by 2,856
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
How Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis
Shojania, K. G., Sampson, M., Ansari, M. T., Ji, J., Doucette, S., & Moher, D. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-4-200708210-00179 · Cited by 838
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
Kris, M. G., Hesketh, P. J., Somerfield, M. R., Feyer, P., Clark-Snow, R., Koeller, J. M., Morrow, G. R., Chinnery, L. W., Chesney, M. J., Gralla, R. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9591 · Cited by 740
Self-citationRoila, F., Herrstedt, J., Aapro, M., Gralla, R. J., Einhorn, L. H., Ballatori, E., Bria, E., Clark-Snow, R. A., Espersen, B. T., Feyer, P., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq194 · Cited by 680
Self-citationRecommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
Gralla, R. J., Osoba, D., Kris, M. G., Kirkbride, P., Hesketh, P. J., Chinnery, L. W., Clark-Snow, R., Gill, D. P., Groshen, S., Grunberg, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2971 · Cited by 664
Self-citation
Cited by
Baracos, V. E., Martin, L., Korc, M., Guttridge, D. C., & Fearon, K. C. H. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.105 · Cited by 1,738
Preventing and Managing Toxicities of High-Dose Methotrexate
Howard, S. C., McCormick, J., Pui, C.-H., Buddington, R. K., & Harvey, R. D. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0164 · Cited by 929
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., Danso, M. A., Dennis, K., Dupuis, L. L., Dusetzina, S. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.4789 · Cited by 628
Self-citationAntiemetics: ASCO Guideline Update
Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., Danso, M. A., Dennis, K., Dupuis, L. L., Dusetzina, S. B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01296 · Cited by 470
Self-citationOlanzapine for the prevention of chemotherapy-induced nausea and vomiting.
Navari, R. M., Qin, R., Ruddy, K. J., Liu, H., Powell, S. F., Bajaj, M., Dietrich, L., Biggs, D., Lafky, J. M., & Loprinzi, C. L. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515725 · Cited by 452
Lyman, G. H., Greenlee, H., Bohlke, K., Bao, T., DeMichele, A. M., Deng, G. E., Fouladbakhsh, J. M., Gil, B., Hershman, D. L., Mansfield, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2721 · Cited by 417
Self-citationHenson, L. A., Maddocks, M., Evans, C., Davidson, M., Hicks, S., & Higginson, I. J. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00470 · Cited by 367
Forastiere, A. A., Ismaila, N., Lewin, J. S., Nathan, C. A., Adelstein, D. J., Eisbruch, A., Fass, G., Fisher, S. G., Laurie, S. A., Le, Q.-T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7385 · Cited by 364
Aapro, M., Molassiotis, A., Dicato, M., Peláez, I., Rodríguez-Lescure, Á., Pastorelli, D., Ma, L., Burke, T., Gu, A., Gascon, P., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds021 · Cited by 308
Abrams, D. I. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.003 · Cited by 296
GDF15 induces anorexia through nausea and emesis
Borner, T., Shaulson, E. D., Ghidewon, M. Y., Barnett, A. B., Horn, C. C., Doyle, R. P., Grill, H. J., Hayes, M. R., & De Jonghe, B. C. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.12.004 · Cited by 255
Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Smith, L. A., Azariah, F., Lavender, V. T., Stoner, N. S., & Bettiol, S. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009464.pub2 · Cited by 255
Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends
Gupta, K., Walton, R., & Kataria, S. P. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100278 · Cited by 231
Navari, R. M. (2013) · Drugs · doi:10.1007/s40265-013-0019-1 · Cited by 174
“Supportive Care in Cancer (MASCC) and the European Society of Medical Oncology (ESMO) [12], the American Society of Clinical Oncology (ASCO) [13] and the National Comprehensive Cancer Network (NCCN) guidelines [14].”
BackgroundMethodInfluentialOhmachi, K., Niitsu, N., Uchida, T., Kim, S. J., Ando, K., Takahashi, N., Takahashi, N., Uike, N., Eom, H. S., Chae, Y. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5203 · Cited by 171
Tafelski, S., Häuser, W., & Schäfer, M. (2016) · Der Schmerz · doi:10.1007/s00482-015-0092-3 · Cited by 71
Han, H. S., Park, J. C., Park, S. Y., Lee, K. T., Bae, S. B., Kim, H. J., Kim, S., Yun, H. J., Bae, W. K., Shim, H.-J., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0211 · Cited by 34
Harder, S., Groenvold, M., Isaksen, J., Sigaard, J., Frandsen, K. B., Neergaard, M. A., Mondrup, L., & Herrstedt, J. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-018-4593-3 · Cited by 17
Arsenic Trioxide and Tretinoin (AsO/ATRA) for Acute Promyelocytic Leukemia (APL)
Damery, E., Solimando, D. A., & Waddell, J. A. (2016) · Hospital Pharmacy · doi:10.1310/hpj5108-628 · Cited by 7
Metadata
- Authors
- Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Feyer, P. C., Somerfield, M. R., Chesney, M., Clark-Snow, R. A., Flaherty, A. M., Freundlich, B., Morrow, G., Rao, K. V., Schwartz, & Lyman, G. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-11-01
- Volume
- 29
- Issue
- 31
- Pages
- 4189-4198
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2123267000
- Cited by
- 1,059
- References
- 43
- FWCI
- 81.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.